To investigate potential mechanisms controlling protein glycosylation we have studied the interrelationship between lymphocytic galactosyltransferase (GTase) activity and serum agalactosylated immunoglobulin G levels (G(0)) in healthy individuals and patients with rheumatoid arthritis and non-autoimmune arthritis. In RA there was reduced GTase activity and increased G(0). A positive linear correlation between B and T cell GTase was found in all individuals. The relationship between GTase and G(0) was found to be positive and linear in the control population and negative and linear in the RA population. Sulphasalazine therapy maintained normal levels of GTase and caused a reduction in G(0) in the RA population. IgG anti-GTase antibodies (abs) were significantly increased in the RA population, whereas IgM anti-GTase abs were significantly decreased in both the RA and the non-autoimmune arthritis groups. These data describe a defect in RA lymphocytic
Introduction
Glycoproteins are ubiquitous in nature (1) and come in a variety of shapes and forms (2) . The majority of molecules involved in the immune system are glycosylated, for example, the HLA class II molecules and the T cell receptor (3, 4) , and tend to exhibit normal variation in the extent of glycosylation (5) . Glycosylation changes can have profound effects on glycoprotein function (6) , and the relevance of IgG glycosylation thought to be located on chromosome 9 (12) , and it may specify more than one mRNA transcript (13) .
GTase seems to play a multifunctional role in normal cell physiology and has been associated with sperm-egg binding (14) , cell-cell recognition (15) , embryonic maturation (16) , and cell development (17) . GTase activity has been shown to be reduced in B lymphocytes of patients with rheumatoid arthritis (18) , but this does not appear to be due to gross structural changes in either the GTase activator gene (19) , the GTase gene itself, or to the presence of a soluble intracellular inhibitor (20) .
Immunoglobulin G is a glycoprotein carrying N-linked oligosaccharides (21) (Fig. 1) which, in the human, are predominantly located at asparagine 297 in the Cy2 domain of the Fc region. There is a parabolic relationship between the extent of galactosylation of the biantennary oligosaccharides and age (22) , with a high percentage of agalactosylated IgG (IgG G(0)) being present at birth and in old age. Oligosaccharide side chains may play an important role in the integrity of IgG as their absence alters not only the conformation of the molecule (23) , but also its functional properties. For example, binding to monocyte and macrophage Fc receptors (24, 25) , complement component C I q (26), and ability to induce cellular cytotoxicity (24) , all rely on a normal degree of glycosylation. Immune complexes containing aglycosylated immunoglobulin fail to be eliminated rapidly from circulation (25) , and feedback immunosuppression is lost (27) .
Abnormalities of IgG glycosylation are recognized in individuals with rheumatoid arthritis (21) , where a shift in the population of IgG glycoforms towards those with a higher content of G(0)-oligosaccharides is observed in both serum and synovial fluid, when compared to age-matched controls. In some of these individuals G(0) levels correlate with clinical score and posing biantennary oligosaccharide structures. The blue spheres represent mannose, the yellow spheres N-acetylglucosamine, the red spheres galactose, the gray/blue spheres fucose, and the green sphere proline 238. The terminal galactose is absent from one ofthe arms of the left hand oligosaccharide moiety exposing amino acid residues that become potentially available for immune interaction.
with Sjogren's syndrome, erythema nodosum leprosum (30) , and Lyme disease-associated arthritis (31) . We now present data to show the interrelationship between lymphocytic GTase and serum IgG G(O) in normal and disease conditions, the effects ofdrug therapy on these parameters, and the association ofisotype-specific serum antigalactosyltransferase antibodies, by investigating populations of healthy individuals, patients with non-autoimmune arthritis, and those with rheumatoid arthritis.
Methods
Patients and healthy individuals THE CONTROL POPULATION Peripheral blood lymphocyte investigations. The control population consisted of 14 patients attending the Bloomsbury Rheumatology Unit and 18 healthy individuals. None of them had an autoimmune rheumatic disease (32) . Their mean age was 54.5 yr (range 32-78 yr) and there were 22 females. 11 members of the patient population were receiving treatment for osteoarthritis, and one individual was taking a nonsteroidal antiinflammatory drug (NSAID). The remaining three patients had ankylosing spondylitis, and two were taking NSAIDs. The healthy individuals had no complaints of arthritis and were taking no drugs.
Tonsil lymphocyte investigations. Lymphocytes were taken from tonsil tissue from nine individuals (mean age 11 yr, range 3-26 yr) who had undergone routine tonsillectomy for benign tonsillar hypertrophy. (33) , were selected at random from those attending the Bloomsbury Rheumatology Unit. Their mean age was 59.9 yr (range 28-88 yr) and they were age matched with the controls to within 10 yr.
Patient treatment. Patients were divided into three groups, according to treatment. Group I (n = 9): who were taking either no medication (n = 5) or a NSAID (n = 4) only. Group 2 (n = 11): who were taking SASP either alone (n = 3), in combination with a NSAID (n = 5), or another drug (n = 3, two on prednisolone, one on azathioprine). Group 3 (n = 12): who were taking second/third line drugs, other than SASP (n = 7), together with a NSAID (n = 5). Of these patients, five were taking D-penicillamine, four azathioprine, two prednisolone, and one sodium aurothiomalate, in conventional doses. All patients had been established on treatment for a minimum of two months.
Disease activity. Disease activity was determined (34) , and graded one to three corresponding to "inactive/mild," "moderate," and "severe" activity.
Disease activity was not equally represented in the three treatment groups, and there were proportionately more individuals with inactive/ mild and moderate disease activity in drug groups 1 and 3 (67% and 83%, respectively) and with moderate and severe disease activity in drug group 2 (9 1%). , before they received medication (n = 12) and after they were established on SASP treatment, at a conventional dose (n = 8). A mean period of 10 mo (range 1-32) separated the investigations while no treatment was being given and a mean period of20 mo (range 13-34) separated the investigations conducted just before the start of SASP and that carried out once the patients were established on SASP.
Experimental procedures
Isolation ofB and T cell-enriched populationsfrom human peripheral blood. Isolation of enriched populations of B and T lymphocytes has previously been described (18) . Briefly, peripheral blood was obtained by venesection and depleted ofmonocytes by incubation with carbonyl iron, followed by separation with a magnet. Peripheral blood lymphocytes were then separated by means ofFicoll-Hypaque (35) . Cell purity was assessed by May-Grunwald-Giemsa staining, the lymphocytes accounting for at least 95% ofthe total population. The B and T cells were further separated by rosetting with neuraminidase-treated sheep red blood cells. Assessment ofcell purity by rerosetting showed at least 95% rosettes in the T cell population and no more than 10% rosettes in the B cell population. The serum samples, diluted in PBS-T, 1% BSA, 3% goat serum at 1/400, were added in duplicate and incubated for 2 h at room temperature. The plates were washed 3X with PBS-T, followed by the addition ofgoat anti-human IgG/M alkaline phosphatase conjugate at 1/1,000, incubated overnight at 4VC, washed 3X with PBS-T, and developed using phosphatase substrate tablets (104; Sigma). The Immunoglobulin G galactosylation. The mean serum G(0) (±SEM) of the total control population was 31.3±1.5%; 0.36±0.2 SD above the age-related population mean previously established. There was no difference in serum G(0) values between the normal and the non-autoimmune arthritis control individuals (normal: G(0) 31.5±2.3%; 0.4'6±0.3 SD above the age-related population mean. Non-autoimmune arthritis: G(0) 31.1±2.0%; 0.24±0.3 SD above the age-related population mean). Regression analysis (Fig. 4) revealed weak linear positive relationships between B/T cell GTase and G(O) (r = 0.263 and 0.211 for B and T'cell GTase, respectively; P < 0.05).
Glycosylation differences within the RA population OVERALL LYMPHOCYTIC GTase ACTIVITY B and T cell populations. Both B and T cell GTase activities (Table II, Figs. 5 and 6) were significantly reduced by 40% (P < 0.01) and 29% (P < 0.05), respectively, when patients were compared to the age-matched control population. There was no difference in GTase activity when the female (n = 27) and the male (n = 5) patients were compared: female, 22±4 and 24±4 cpm/mg protein * 05; male, 19±7 and 9±4 cpm/mg protein l05 for B and T cells, respectively.
Regression analysis (Fig. 3) -The Tcellpopulation. In drug groups 1 and 3 (Fig. 6 ) GTase activity was significantly reduced (P < 0.05) by 42% and 32%, respectively, when compared'to the total control population. As was the case with' B cells, there was no significant difference when GTase activity ofdrug group 2 was compared to the total control population, and again a significant reduction in GTase activities was observed in patients in'drug groups 1 and 3 when compared to those in drug group 2 Regression analysis revealed a strong positive linear relationship between B and T cell GTase activity in both drug group 1 and 2 patients (r = 0.824 and 0.772 for groups 1 and 2, respectively, P < 0.01), but a similar relationship was not found with drug group 3 patients (r = 0.240).
IMMUNOGLOBULIN G GALACTOSYLATION
In accordance with previous studies (21, 36), the G(0) values of the RA population (38.1±1.9%; 1.1±0.2 SD above the age-related population mean) were significantly greater than those of the corresponding age-matched control population (P < 0.01). There was no significant difference between G(0) values analyzed according to sex, drug group, and disease activity, and there was no correlation between G(0) and age in this population. Regression analysis (Fig. 7) revealed a negative linear relationship between G(0) and B cell GTase, but not T cell GTase activity (r = -0.16, P = 0.1). Comparison of regression values for GTase and G(0) between the-control and RA populations revealed a significant difference for both B cells (P < 0.01) and T cells (P < 0.05). (Significance ofdifference from controls: * P < 0.01; ** P < 0.02; *** P < 0.05).
CONSECUTIVE PATIENT INVESTIGATION
Galactosyltransferase activity. In the group treated with drugs other than SASP (n = 6, 19 investigations), there was a significant decrease in the B cell GTase activity (13±2 cpm/mg protein * 10) when compared to both the total control population (P < 0.05) and the consecutive patient group taking SASP ( Fig.  9 , P < 0.05). The T cell GTase activity (18±4 cpm/mg protein* 10) was not different from the total control population, but was significantly reduced when compared to the consecutive patient group taking SASP (P < 0.05).
Immunoglobulin G galactosylation. In those patients (RA second group) observed on two occasions before sulphasalazine treatment was commenced, there was no significant difference between the paired serum IgG G(O) values (33.8±2.5%; 0.9±0.3 SD and 28.0±2.3%; 0.02±0.03 SD above the age-related population mean). However, there was a significant difference in paired serum G(O) values (Fig. 10) Figure 9 . A comparison of lymphocytic GTase activity in RA patients (n -13) taking second/third line drugs other than SASP (Other Drugs, n = 6, 19 investigations) and those taking SASP (n = 7, 24 investigations), showing a significant reduction (P < 0.05) in lymphocytic GTase activity within the RA group taking other drugs. There was no difference in lymphocytic GTase activity between the SASP group and the total control population.
diating these changes may operate. An association between paired B and T cell GTase activities was detected, and this may suggest parallel regulatory control. In RA, previous data indicating a reduced B cell GTase activity (18) have been confirmed when the sample population was increased, and these findings have since been verified (38) . A positive correlation between B and T cell GTase activity was again found, although the use of certain second and third line drugs (group 3) obscured this relationship, which may indicate that these drugs interfere with B and T cell control. G(0) and B cell GTase values were weakly associated, but in contrast to the normal population, a negative rather than a positive relationship was observed. This may indicate a breakdown in the normal regulatory mechanisms. No significant association was 60 
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U. No relationship between clinical disease activity and GTase activity or G(O) values was apparent in the RA patients studied, which contrasts with previously reported G(0) observations in individual patients (28) . This may suggest that drug suppression of inflammation obscures ongoing disease activity. Perhaps the development ofjoint erosions or the presence of inflammatory mediators within thejoint would be a more appropriate, although impractical, measure of disease activity in this study. However, the lack of association with clinical disease activity and correlation between GTase and G(0) points to the abnormality being primarily a synthetic defect rather than being due to inflammation (37) . In this respect, additional evi- specific GTase isoenzyme changes rather than total enzyme activities, and more meaningful to examine individual patient fluctuations in glycosylation values, as these changes may be highly patient specific. Other diseases are associated with glycosylation changes and, perhaps, the mechanism of these changes may have some relevance to the pathogenesis of autoimmunity. Reduced activity of a glycosaminoglycan glycosyltransferase (44) has been reported in hereditary collagen disease and depressed levels of serum GTase are found in patients with cystic fibrosis (45) . Elevation of serum GTase activity has been reported in the presence of tumor tissue (46) , and serial determinations are thought to correlate with clinical status (47) . Furthermore, cancer-associated isoenzyme changes have also been observed (48) .
When the RA population was divided according to drug therapy, there was little difference in GTase activity between those taking no medication or NSAIDs (group 1) and those taking second or third line drugs (group 3), which were both significantly reduced in comparison to the control population. These data would indicate that drug therapy itself does not reduce GTase activity. However, no reduction was noted in B or T cell GTase activity in those taking SASP, when compared to the control population. Furthermore, when those taking SASP were compared to those in drug groups 1 and 3, there was a significant reduction in activity in the other drug groups when compared to the SASP group. This finding has since been observed in six other patients taking SASP (data not shown). When seven ofthe patients from group 2 ofthe RA cohort were investigated on a number of occasions once they had been established on SASP, the effect of SASP on GTase activity was maintained, in contrast to those taking other drugs. A longitudinal study of a different group of RA patients produced entirely comparable results in that a significant decrease in G (0) value was seen when SASP was established. It is possible that SASP has a direct pharmacological effect on B cell GTase activity and G(0) value, and what makes this a potentially useful observation is that SASP is now an established second line antirheumatic agent for the treatment of RA (49, 50) . Interestingly, serum concentrations of SASP in patients with RA are low, unrelated to clinical effects (51), and do not reach levels required to inhibit mitogen stimulation of lymphocytes (52) , although in vitro inhibition of immunoglobulin synthesis and rheumatoid factor production is seen (53). Conceivably, SASP has an antibiotic effect on gut flora, thus altering the variety of antigens crossing the gut wall, or it may be that the intact SASP molecule exerts its effects by local suppression of lymphoid tissue in the small intestine (52) , which in turn affects the lymphocyte traffic pathways of cells emerging from the gut-associated lymphoid tissue (54) . In this respect, it may be more than coincident that RA intestinal mucin is abnormally glycosylated (55) , and it remains to be seen whether there is an associated concomitant intestinal GTase defect. Preliminary in vitro investigations (data not shown) have been carried out to study the biochemical relationship between SASP, its metabolites sulphapyridine and 5-aminosalicylic acid (52) , and GTase activity. In concentrations corresponding to those detected in the serum of SASP-treated patients (0-10 Ijg/ml), SASP has a direct dose-dependent inhibitory effect on human milk GTase and lymphocytic GTase from healthy and RA individuals, which is also observed indirectly when SASP is incubated with cultured lymphocytes. Similar effects are not observed when sulphapyridine and 5-aminosalicylic acid are used. These initial data would indicate that SASP and its metabolites do not have a direct synergistic effect on GTase activity. Perhaps SASP causes a GTase isoenzyme shift that proportionately increases IgG-galactosylation, or maybe SASP and/or its metabolites exhibit GTase synergism only in certain individuals who have RA.
Although IgG function may significantly alter as a result of oligosaccharide changes (24) (25) (26) (27) , evidence is lacking to link these changes with autoimmunity. The role played by oligosaccharides in causing IgG autosensitization and immune complex formation has been much debated (56), especially as the immunogenic site on IgG is thought to be localized to the Fc moiety (57, 58) . There is, however, no evidence for amino acid changes in IgG-Fc, but immune complex formation in rheumatoid arthritis may occur either as a result of self-associating abnormally glycosylated immunoglobulins, or through the interaction with antibodies induced against N-acetylglucosamine, the peptide, or peptide-oligosaccharide epitopes, that are normally unavailable for interaction. An analogous situation to this is found with recombinant human granulocyte macrophage colony stimulating factor, where antibodies are formed in patients against the recombinant protein only when the aglycosylated form is used (59) . However, it has been observed that the in vitro binding of IgM rheumatoid factor to solid phase IgG-Fc fragments is influenced by the Fc-isotype rather than by the degree of Fc-glycosylation (60), but it has also been suggested that the Fc-oligosaccharides are unavailable for interaction, being hidden within the molecule, and it is the change in Ig conformation that results in functional abnormalities (23) .
To investigate whether there is a humoral component associated with these glycosylation changes, the presence of antiGTase antibodies (abs) was sought in the serum ofRA, non-autoimmune arthritis, and healthy individuals, and the presence of isotype-specific serum anti-GTase abs was detected. In RA, IgG anti-GTase antibody levels were significantly increased when compared to both the non-autoimmune arthritis (119%) and healthy control populations (84%), and 36% of the RA population had levels greater than healthy control mean + 2 SD. In contrast, IgM anti-GTase levels were significantly decreased in both the RA (-18%) and the non-autoimmune arthritis populations (-53%) when compared to the healthy control population. No association was found between anti-GTase antibody levels and disease activity parameters or drug treatment. These data suggest that naturally occurring IgM anti-GTase antibodies are part of a normal immune regulatory mechanism associated with physiological glycosylation changes, whereas IgG anti-GTase antibodies result from isotype switching in RA that is associated with aberrant regulation of glycosylation. A further significant aspect of these data is that the presence of IgG anti-GTase antibodies is only associated with RA and not with non-autoimmune arthritis, whereas both these disease groups have less than normal levels of IgM. This raises the possibility that other immune-regulated glycosylation changes, as yet undetected, may be associated with other forms of rheumatic disease. It is also pertinent that these changes are unrelated to clinical disease activity, ESR, and IgM rheumatoid factor, which would suggest that they are not inflammation-related epiphenomena. These data now need to be further substantiated by investigating other diseases that are known to be associated with glycosylation changes (for example, systemic lupus erythematosus and Crohn's disease) This discussion has focused on IgG, and hence the B lymphocyte, but it is known that other immunologically pertinent molecules are glycosylated (3, 4) and previous data (18) suggesting a reduction in T cell GTase activity has also been verified in this paper. T cell membrane proteins (i.e., T cell receptor, major histocompatability complex molecules, and lymphocyte functional antigens) and secreted lymphokines may be abnormally glycosylated and also contribute to dysregulate the immune function.
In conclusion, correlation between B and T cell GTase activities has been observed in both normal and RA individuals, which would imply a mechanism of galactosylation control encompassing regulation of both lymphocytic populations. This regulatory mechanism may ensure certain levels of IgG glycosylation, and perhaps of other glycoproteins, in the normal population, which could become defective in RA. Serum anti-GTase abs may form part ofthis process, and there may be isotype switching of the naturally occurring IgM abs, found in healthy individuals, to RA-related IgG abs. Changes in these parameters may play a direct role in the pathogenesis of RA by forming part of the mosaic of susceptibility factors to RA, and manipulation of these changes, either by correcting the abnormal oligosaccharide or increasing the activity of GTase, may form the basis ofa novel therapeutic approach to the treatment ofRA. The fact that SASP has a marked and sustained effect on lymphocytic GTase and disease activity (51, 52) 
